Multiple TAA-loaded Dendritic Cell Vaccine clinical trials
How each study uses Multiple TAA-loaded Dendritic Cell Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Multiple TAA-loaded Dendritic Cell Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MASCT-I
- 4
Studies by the year they started
6 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
HRYZ Biotech Co. (5) · The First People's Hospital of Lianyungang (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Multiple TAA-loaded Dendritic Cell Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue SarcomaRecruitingPhase 2HRYZ Biotech Co.NCT06277154Written as MASCT-I
- MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingEarly Phase 1HRYZ Biotech Co.NCT04074564Written as MASCT-I, Camrelizumab,Apatinib
- A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid TumorsTerminatedPhase 1HRYZ Biotech Co.NCT03034304Written as MASCT-I
- MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.CompletedPhase 1HRYZ Biotech Co.NCT05877651Written as MASCT-I injection
- A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild TumorStatus unknownPhase 1HRYZ Biotech Co.NCT03393416Written as MASCT-I
- MASCT-I Treatment for Advanced Solid TumorStatus unknownPhase 1/2The First People's Hospital of LianyungangNCT02858232Written as MASCT-I